BjörndalA, DengH, JanssonM, FioreJRet al.Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol, 1997; 71,10:7478–7487.
2.
MoyleG, WildfireA, MandaliaSet al.Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis, 2005; 191:866–872.
3.
AngaranoG, MonnoL, FioreJR, FracassoC, La GrastaL, RomanelliC. Prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users in south-eastern Italy. AIDS, 1996; 10,7:805–806.
4.
AngaranoG, PastoreG, MonnoLet al.Rapid spread of HTLV-III infection among drug addicts in Italy. Lancet, 1985; ii:52.
5.
SpijkermanJ, KootM, PrinsMet al.Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men. AIDS, 1995; 9:1085–1092.
6.
MonnoL, CarbonaraS, CiracìEet al.Twenty years later: The recent trends of HIV-infection. Evidence from an Italian region. Infection, 2007; 35,6:481–483.
7.
de MendozaC, RodriguezC, GarcíaFet al.Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. J Antimicrob Chemother, 2007; 59,4:698–704.
8.
SoulieC, FouratiS, Lambert-NiclotSet al.Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: Implications for the clinical use of CCR5 antagonists. J Antimicrob Chemother, 2010; 65:749–751.
